Both metformin and GLP-1 RAs have been studies for their neuroprotective effects; this study is the first head-to-head investigation and supports further research.
Eisai will present four-year safety and efficacy data, real-world use patterns, and findings on a new subcutaneous formulation for maintenance treatment in early Alzheimer disease.
In recognition of World Brain Day, Anna Chodos, MD, discusses why early detection of cognitive decline must become standard practice—and how PCPs can take simple, effective steps to make that happen.